Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
8
×
life sciences
national blog main
national top stories
8
×
new york blog main
new york top stories
san francisco blog main
san francisco top stories
clinical trials
fda
national
san diego blog main
san diego top stories
startups
boulder/denver blog main
boulder/denver top stories
cancer immunotherapy
deals
detroit blog main
detroit top stories
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
investing
nonalcoholic steatohepatitis
president trump
abbvie
acute myeloid leukemia
amgen
astrazeneca
avexis
What
biotech
8
×
new
roundup
bio
days
drug
medicines
research
annual
attention
control
diseases
drugs
ipo
news
raised
startup
today
week
according
ahead
aiming
aims
akcea
alzheimer’s
ambien
ambys
american
analysis
approach
arrival
asco
assessed
attendees
august
based
big
bring
busy
called
Language
unset
Current search:
biotech
×
" boston top stories "
×
" national top stories "
×
@xconomy.com
3 years ago
Two Days, Six IPOs, and $1B Raised for Biotech Research & More
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
@xconomy.com
6 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More